The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Min-Hee Kwon
- Phone Number: 02-526-3379
- Email: minhee@ildong.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Gil Medical Center
-
Contact:
- Tae Hoon Ahn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hypercholesterolemic patient
Exclusion Criteria:
- Has history of hypersensitivity to HMG-CoA reductase inhibitor and Ezetimibe
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: R5
Rosuvastatin 5mg
|
Rosuvastatin 5mg
|
|
Active Comparator: R10
Rosuvastatin 10mg
|
Rosuvastatin 5mg
|
|
Active Comparator: R20
Rosuvastatin 20mg
|
Rosuvastatin 5mg
|
|
Experimental: R5/E10
Rosuvastatin 5mg/ezetimibe 10mg
|
Rosuvastatin 5mg
|
|
Experimental: R10/E10
Rosuvastatin 10mg/ezetimibe 10mg
|
Rosuvastatin 5mg
|
|
Experimental: R20/E10
Rosuvastatin 20mg/ezetimibe 10mg
|
Rosuvastatin 5mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change from baseline to 8 week in LDL-Cholesterol
Time Frame: baseline and 8 week
|
baseline and 8 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change from baseline to 4 week in LDL-Cholesterol
Time Frame: baseline and 4 week
|
baseline and 4 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Tae Hoon Ahn, Gachon University Gil Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Hypercholesterolemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Rosuvastatin Calcium
- Ezetimibe
Other Study ID Numbers
Other Study ID Numbers
- ID-ROEZ-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.